Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05390515
PHASE4

Psoriatic Immune Response to Tildrakizumab

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2022-09-01

Completion Date

2028-09-01

Last Updated

2026-06-04

Healthy Volunteers

No

Interventions

DRUG

Tildrakizumab Prefilled Syringe

IL-23 inhibitor

Locations (1)

University of California, San Francisco

San Francisco, California, United States